Similar Items: PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure
- Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER
- Correction: Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER
- Tetrahydrocurcumin (THC) as a Melanogenesis Inhibitor in Melanoma Cell Lines
- A Cost Analysis of Adverse Event Management of Systemic Therapies for Metastatic Colorectal Cancer on Patients with at Least Two Previous Lines of Treatment in Spain
- Disproportionality analysis of fondaparinux associated adverse events based on the FDA adverse event reporting system
- Exploring adverse events associated with vosoritide monotherapy: Insights from the FDA Adverse Event Reporting System